Hypocretin ligand deficiency in narcolepsy: Recent basic and clinical insights

Current Neurology and Neuroscience Reports

Volumn 10, Issue 3, 2010, Pages 180-189

  Ritchie, Cayde ^a   Okuro, Masashi ^a   Kanbayashi, Takashi ^b   Nishino, Seiji ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AKITA UNIVERSITY   (Japan)

Author keywords

Cataplexy; CSF; EDS; Histamine; Hypocretin; MS; Narcolepsy; NMO; Orexin; REM sleep

Indexed keywords

AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; IMMUNOGLOBULIN; MODAFINIL; OREXIN; OREXIN A; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 2; AQUAPORIN 4; G PROTEIN COUPLED RECEPTOR; IMMUNOLOGIC FACTOR; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; OREXIN RECEPTORS; OREXINS; SIGNAL PEPTIDE;

APOPTOSIS; AUTOIMMUNITY; BRAIN NERVE CELL; CATAPLEXY; CELL TRANSPLANTATION; DAYTIME SOMNOLENCE; DIAGNOSTIC TEST; DRUG EFFICACY; GENE THERAPY; GENETIC LINKAGE; GENETIC POLYMORPHISM; HUMAN; HYPNAGOGIC HALLUCINATION; HYPOCRETIN LIGAND DEFICIENCY; HYPOTHALAMUS LESION; IMMUNOMODULATION; NARCOLEPSY; NONHUMAN; NONREM SLEEP; PARASOMNIA; PATHOPHYSIOLOGY; PROTEIN DEFICIENCY; REM SLEEP; REVIEW; SYMPTOM; ANIMAL; CELL DEATH; GENETICS; IMMUNOLOGY; METABOLISM; NERVE CELL; PHYSIOLOGY; SLEEP;

ANIMALS; AQUAPORIN 4; CELL DEATH; HUMANS; IMMUNOLOGIC FACTORS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NARCOLEPSY; NEURONS; NEUROPEPTIDES; POLYMORPHISM, GENETIC; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NEUROPEPTIDE; SLEEP;

EID: 77954926317     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-010-0100-z     Document Type: Review

References (53)

1. Nishino S, Kanbayashi T: Symptomatic narcolepsy, cataplexy, and hypersomnia, and their implications in the hypothalamic hypocretin/ orexin system. Sleep Med Rev 2005, 9:269-310.
2. • Nishino S: Clinical and neurobiological aspects of narcolepsy. Sleep Med 2007, 8:373-399. The author examines the centrality of hypocretin neurotransmission impairment to the pathophysiologic mechanism in narcolepsy and the potential of ligand replacement as a relevant therapeutic option in view of the results of recent animal studies.
3. Mignot E, Lammers GJ, Ripley B, et al.: The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
4. Nishino S: The hypocretin/orexin system in health and disease. Bio Psychiatry 2003, 54:87-95.
5. Nishino S, Mignot E: Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997, 52:27-78.
6. Nishino S, Taheri S, Black J, et al.: The neurobiology of sleep in relation to mental illness. In Neurobiology of Mental Illness. Edited by Charney DS, Nestler EJ. New York: Oxford University Press; 2004:1160-1179.
7. Espana RA, Scammell TE: Sleep neurobiology for the clinician. Sleep 2004, 27:811-820.
8. Aldrich MS, Chervin RD, Marlow BA: Value of the multiple sleep latency test (MSLT) for diagnosis of narcolepsy. Sleep 1997, 20:620-629.
9. Takeuchi T, Miyasist A, Sasaki Y, et al.: Isolated sleep paralysis elicited by sleep interruption. Sleep 1992, 15:217-225.
10. Sakurai T, Amemiya A, Ishii M, et al.: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G proteincoupled receptors that regulate feeding behavior. Cell 1998, 92:573-585.
11. De Lecca L, Kilduff TS, Peyron C, et al.: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322-327.
12. Peyron C, Tighe DK, van den Pol AN, et al.: Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998, 18:9996-10015.
13. Lin L, Faraco J, Li R, et al.: The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell 1999, 98:365-376.
14. Chemelli RM, Willie JT, Sinton CM, et al.: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 1999, 98:437-451.
15. Nishino S, Ripley B, Overeem S, et al.: Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
16. Peyron C, Faraco J, Rogers W, et al.: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
17. Nishino S, Ripley B, Overeen S, et al.: Low CSF hypocretin (orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001, 50:381-388.
18. American Academy of Sleep Medicine: The International Classification of Sleep Disorders Diagnostic and Coding Manual, edn 2. Winchester, IL: American Academy of Sleep Medicine; 2005.
19. Honda Y: Clinical features of narcolepsy: Japanese experience. In HLA in Narcolepsy. Edited by Honda Y, Juji T. New York: Springer-Verlag; 1988:24-57.
20. Kanbayashi T, Inoue Y, Chiba S, et al.: CSF hypocretin-1 (orexin- A) concentrations in narcolepsy with and without cataplexy and idiopathic hypersomnia. J Sleep Res 2002, 11:91-93.
21. Blouin AM, Thannickal TC, Worley PF, et al.: Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy. Neurology 2005, 65:11189-11192.
22. Crocker A, Espana RE, Papdopoulou M, et al.: Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005, 65:1184-1188.
23. • Honda M, Eriksson KS, Zhang S, et al.: IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS One 2009, 4:e4254. This article discusses the recent identification of IGFBP3, thereby underscoring selective hypocretin cell death, as opposed to transcription/biosynthesis or hypocretin peptide processing problems, as the cause of hypocretin deficiency.
24. Billiard M, Laaberki MF, Reygrobellet C, et al.: Elevated antibodies to streptococcal antigens in narcoleptic subjects. Sleep Res 1989, 18:201.
25. • Dauvilliers Y, Arnulf I, Mignot E: Narcolepsy with cataplexy. Lancet 2007, 369:499-511. This article discusses the possibility that transient autoimmune reaction in the CNS coincides with disease onset despite the failure to find typical autoimmune pathologies or to implicate neuron-specific/organ- specific autoimmune antibodies or IgG reactive to prepro-hypocretin or cleavage products in narcoleptic patients.
26. • Aran A, Lin L, Nevsimalova S, et al.: Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009, 32 (8):979-983. This recent, significant study evaluated Streptococcus pyogenes and Helicobacter pylori infections as triggers for narcolepsy. The study compared 200 hypocretin-deficient narcolepsy patients with 200 age-matched controls to find that patients exhibited significantly higher immune response markers close to narcolepsy onset. These findings underscore the probability that streptococcal infections are significant environmental triggers for narcolepsy.
27. Mignot E: Genetic and familial aspects of narcolepsy. Neurology 1998, 50:S16-S22.
28. Hohjoh H, Nakayama T, Ohashi J, et al.: Significant association of the tumor necrosis factor receptor 2 (TNFR2) gene with human narcolepsy. Tissue Antigens 2000, 56:446-448.
29. Dauvilliers Y, Neidhart E, Lecendreux M, et al.: MAO-A and COMT polymorphisms and gene effects in narcolepsy. Mol Psychiatry 2001, 6:367-372.
30. • Miyagawa T, Kawashima M, Nishida N, et al.: Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 2008, 40:1324-1328. These familial and twin studies examining gene polymorphisms associated with narcolepsy specifically indicate that the predictive genes of narcolepsy may exacerbate narcolepsy sleep phenotype and/or engage mechanisms of hypocretin cell death.
31. Park MH, Roh EY, Park H, et al.: Association of TNF-alpha gene promoter polymorphism with narcolepsy-cataplexy in Koreans. Hum Immunol 2004, 65:S110.
32. Wieczorek S, Gencik M, Rujescu D, et al.: TNFA promoter polymorphisms and narcolepsy. Tissue Antigens 2003, 61:437-442.
33. Dickenstein JB, Moldofsky H, Lue FA, et al.: Intracerebroventricular injection of TNF-alpha promotes sleep and is recovered in cervical lymph. Am J Physiol 1999, 276:R1018-R1022.
34. Kawashima M, Tamiya G, Oka A, et al.: Genomewide association analysis of human narcolepsy and a new resistance gene. Am J Hum Genet 2006, 79:252-263.
35. Tafti M, Petit B, Chollet D, et al.: Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep. Nat Genet 2003, 34:320-325.
36. Hallmayer J, Faraco J, Lin L, et al.: Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009, 41:708-711.
37. • Verma A, Anand V, Verma NP: Sleep disorders in chronic traumatic brain injury. J Clin Sleep Med 2007, 3:357-362. This article identifies percentages of US patients among several million with chronic brain injury who report sleep problems and symptomatic EDS, underscoring the clinical relevance of symptomatic EDS.
38. Scammell TE, Nishino S, Mignot E, et al.: Narcolepsy and low CFS orexin (hypocretin) concentration after diencephalic stroke. Neurology 2001, 56:1751-1753.
39. Marcus CL, Trescher WH, Halbower AC, et al.: Secondary narcolepsy in children with brain tumors. Sleep 200, 25:435-459.
40. Nishino S, Kanbayashi T, Fujiki N, et al.: CSF hypocretin levels in Guillain-Barre syndrome and other inflammatory neuropathies. Neurology 2003, 61:823-825.
41. Overeem S, Dalmau J, Bataller L, et al.: Secondary narcolepsy in patients with paraneoplastic anti-Ma2 antibodies is associated with hypocretin deficiency. J Sleep Res 2001, 11(Suppl.1):166-167.
42. • Kanbayashi T, Shimohata T, Nakashima I, et al.: Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 2009, 66(12):1563-1566. The authors report a significant recent study of symptomatic narcolepsy in patients diagnosed with immune-mediated neurologic condition MS with bilateral hypothalamic inflammatory lesions. The findings specifically link the presence of anti-AQP4 antibody and the probability of immuno-attack in hypothalamic periventricular regions to reduced CSF hypocretin-1 levels. Further, they suggest that additional antibody-mediated mechanisms also contribute to secondary hypocretin system impairment, manifesting in EDS symptoms.
43. Ripley B, Fujiki N, Okura M, et al.: CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258.
44. Tachibana N, Howar RS, Hirsch NP, et al.: Sleep problems in multiple sclerosis. Eur Neurol 1994, 34:320-323.
45. Amiry-Moghaddam M, Ottersen, OP: The molecular basis of water transport in the brain. Nat Rev Neurosci 2003, 4:991-1001.
46. Lennon VA, Kryzer TJ, Pittock SJ, et al.: IgG marker of opticspinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005, 202:473-477.
47. Fujiki N, Ripley B, Yoshida Y, et al.: Effects of IV and ICV hypocretin-1 (orexin A) in hypocretin receptor-2 gene mutated narcoleptic dogs and IV hypocretin-1 replacement therapy in a hypocretin ligand deficient narcoleptic dog. Sleep 2003, 6:953-959.
48. Mieda M, Willie JT, Hara J, et al.: Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice. Proc Natl Acad Sci U S A 2004, 101:4649-4654.
49. • Mishima K, Fujiki N, Yoshida Y, et al.: Hypocretin receptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy. Sleep 2008, 31:1119-1126. This study demonstrated that supplementation of hypocretin-1 by central administration normalized sleep/wake patterns and behavioral arrest episodes in hypocretin cell-ablated narcoleptic (orexin/ataxin-3) mice. It further demonstrated that exogenous expression of the prepro-hypocretin gene rescued sleep fragmentation and cataplexy in the mice, thus supporting further research aimed toward developing cell transplantation and gene therapy treatment options.
50. Ripley B, Fujiki N, Okura M, et al.: Hypocretin levels in sporadic and familial cases of canine narcolepsy. Neurobiol Dis 2001, 8:525-534.
51. Schatzberg SJ, Cutter-Schatzberg K, Nydam D, et al.: Case study: effect of hypocretin ligand replacement therapy in a 3-year-old Weimaraner with narcolepsy. J Vet Intern Med 2004, 18:586-588.
52. Liu M, Thankachan S, Kaur S, et al.: Orexin (hypocretin) gene transfer diminishes narcoleptic sleep behavior in mice. Eur J Neurosci 2008, 28:1382-1393.
53. Arias-Carrion O, Murillo-Rodriguez E, Xu M, et al.: Transplant of hypocretin neurons into the pontine reticular formation: primary results. Sleep 2004, 27:1465-1470.